CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Update

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 7,860,000 shares, a growth of 391.3% from the October 31st total of 1,600,000 shares. Based on an average daily trading volume, of 63,190,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 30.0% of the shares of the company are sold short.

Insider Buying and Selling

In other news, major shareholder Bioventures Opportunities G. Yk sold 3,250,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $0.10, for a total value of $325,000.00. Following the completion of the sale, the insider now directly owns 22,620,783 shares of the company’s stock, valued at $2,262,078.30. This trade represents a 12.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Stuart M. Sloan sold 532,486 shares of the firm’s stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $0.10, for a total value of $53,248.60. Following the completion of the sale, the insider now directly owns 21,067,956 shares of the company’s stock, valued at $2,106,795.60. This represents a 2.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 18.00% of the stock is currently owned by company insiders.

CERo Therapeutics Stock Performance

CERO stock traded up $0.06 during midday trading on Thursday, hitting $0.20. 63,712,566 shares of the stock were exchanged, compared to its average volume of 20,758,256. The stock’s 50-day moving average price is $0.12 and its 200-day moving average price is $0.29. CERo Therapeutics has a fifty-two week low of $0.06 and a fifty-two week high of $12.80.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.